Atlas Trials

Adverum Biotechnologies, Inc.

11 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Adverum Biotechnologies, Inc.

RecordFirmDate
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration (NCT07630649)Adverum Biotechnologies, Inc.2026-06-02
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) (NCT07482176)Adverum Biotechnologies, Inc.2026-03-16
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (NCT06856577)Adverum Biotechnologies, Inc.2025-02-28
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] (NCT05536973)Adverum Biotechnologies, Inc.2022-08-23
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT) (NCT05607810)Adverum Biotechnologies, Inc.2022-08-10
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] (NCT04645212)Adverum Biotechnologies, Inc.2020-12-14
ADVM-022 Intravitreal Gene Therapy for DME (NCT04418427)Adverum Biotechnologies, Inc.2020-05-28
Long-Term Follow-up Study of ADVM-043 (NCT03804021)Adverum Biotechnologies, Inc.2018-12-27
ADVM-022 Intravitreal Gene Therapy for Wet AMD (NCT03748784)Adverum Biotechnologies, Inc.2018-11-14
Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency (NCT02168686)Adverum Biotechnologies, Inc.2017-11-28

Track Adverum Biotechnologies, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.